Quick Answer
Revolution Medicines, Inc. reported Operating Income of -$1.18 billion for fiscal year 2025.
Revolution Medicines, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$1.18B | -71.5% |
| 2024 | -$689.52M | -41.5% |
| 2023 | -$487.19M | -88.6% |
| 2022 | -$258.28M | -37.4% |
| 2021 | -$188.01M | -69.8% |
| 2020 | -$110.70M | -104.5% |
| 2019 | -$54.12M | -34.2% |
| 2018 | -$40.33M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$315.27M | -79.4% | -19.1% |
| June 30, 2025 | -$264.71M | -69.0% | -9.9% |
| March 31, 2025 | -$240.76M | -70.9% | -37.0% |
| September 30, 2024 | -$175.71M | -42.6% | -12.2% |
| June 30, 2024 | -$156.64M | -44.0% | -11.2% |
| March 31, 2024 | -$140.86M | -87.4% | -14.3% |
| September 30, 2023 | -$123.25M | -61.0% | -13.3% |
| June 30, 2023 | -$108.80M | -75.2% | -44.8% |
- Revolution Medicines, Inc. showed a decrease of -71.5% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Revolution Medicines, Inc.’s operating income has declined by 2831.8% (from -$40.33 million to -$1.18 billion).
- The most recent figure is from Revolution Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: